Fig. 6

AngII treatment increases O-GlcNAc levels in the presence of AMPK. WT (in blue) and AMPKα2 KO (in red) mice were treated with or without angiotensin II (AngII, 2 mg/kg/d) for 5 days in order to evaluate O-GlcNAcylated protein levels. a Schematic representation of the experimental protocol where mice were treated for 5 or 14 days in order to evaluate O-GlcNAcylated protein levels or cardiac hypertrophy respectively. b Representative immunoblot of protein O-GlcNAcylation levels in WT and AMPKα2 KO mouse hearts. c Quantification of protein O-GlcNAcylation levels in WT and AMPKα2 KO mouse hearts. N = 6. Data in c are expressed as mean ± s.e.m and were analyzed using Two-way ANOVA followed by Bonferroni post-test. *p < 0.05 vs. untreated WT mice. GAPDH is used as loading control, MW molecular weight